International Health Announces Results of Preliminary Tests for Multiple Avian Bird Flu Strains Using Patented Super Silver Technology™
by Glenn Parhnam
In separate in vitro tests against two strains of the H5N1 avian bird flu subtype, both instances of the virus were successfully neutralized by International Health’s SilverSol Technology™ product, called Super Silver solution. The most recent findings are consistent with prior test using company products against the H3N2 and H1N1 flu subtypes.
SCOTTSDALE — October 9, 2008 — International Health, Scottsdale, Arizona distributor of a line of powerful products that utilize patented SilverSol Technology™ to combat many of the world’s most harmful pathogens, today announced successful preliminary results on tests performed using the Super Silver Solution against three strains of the Avian Bird Flu Virus.
Preliminary in vitro tests performed by two separate independent laboratories, usingInternational Health’s Super Silver Solution at 10 ppm (parts per million) against two strains of the H5-N1 and H3-N2 subtype of the Avian Bird Flu virus, indicated that theSuper Silver products could neutralize the virus.
“While we understand that these are preliminary studies, we are extremely encouraged by the results of this initial testing,” said Glenn Parnham, Director of Research & Development at International Health. “Our intent with these studies is to test the ability of the Super Silver Solution to disarm or kill the Avian Flu virus in a laboratory setting. It is a necessary and valuable next step in our continued efforts to gain an understanding of what this technology can do.”
The preliminary results of the tests using Super Silver products against the H5N1 Avian Bird Flu virus are consistent with a variety of pervious tests conducted using Super Silver products against the H3N2 and H1N1 flu subtypes. In all cases, Super Silver™ was able to successfully neutralize the virus.
International Health is engaged in continuing testing and study programs with variety of groups and labs in the United States and other nations examining the potential applications of the Super Silver Technology™.
For more information, contact Glenn Parnham, Director of Research & Development at International Health, at his research office in Arizona at 480-429-0021.
Bookmark on del.icio.us